Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission

Zhu Weiming

Status and phase

Unknown

Phase 3

Phase 2

Conditions

Gastrointestinal Diseases

Intestinal Diseases

Digestive System Diseases

Crohn's Disease

Inflammatory Bowel Diseases

Treatments

Drug: Mesalazine, Tripterygium glycosides

Study type

Interventional

Funder types

Other

Identifiers

NCT02044952

CDTW-1

Details and patient eligibility

About

The purpose of this study is to assess the effect and safety of Tripterygium Glycosides in the treatment of Crohn's disease for induction remission and compare the therapeutic effect with patients who received mesalazine.

Full description

Crohn's disease is characterized by inflammation and ulceration of the small intestine and colon. Patients commonly experience abdominal pain, diarrhea，malnutrition and malaise which result in decreased quality of life and an increased risk of chronic disability and unemployment.

Tripterygium Glycosides(T2) is a chloroform/methanol extract Tripterygium wilfordii Hook F (TWHF), the traditional Chinese medicine, used in rheumatoid arthritis and nephritis. It has both immune-modulatory and anti-inflammatory activities. Our previous animal studies have revealed that the major component of T2, triptolide, could prevent the development of chronic colitis in interleukin-10 deficient mice. The phase I clinical trial in our institute also demonstrated that T2 is efficient for induction of remission in patients with mild to moderate active crohn's disease. The common adverse effects of T2 are leucopenia, liver renal toxicity, oligospermia and amenorrhea.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects should have a definitive diagnosis of Crohn's disease, based on WHO criteria.
Males and females ≥ 18 years old, including women who are not pregnant or lactating at the time of enrollment.
Subjects should have a CDAI score between 150 to 270 at week 0.
Able to swallow tablets.
Are capable of providing written informed consent and obtained at the time of enrollment.
Willing to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Bacterial, viral or other microbial infection(including HIV).
Orally administered corticosteroids within 3 weeks before enrollment, Inhaled or dermatologic preparations for the treatment of other diseases are acceptable.
Used of infliximab or immunosuppressant within 2 months before enrollment.
Previous use of prescription doses of NSAIDs without efficacy.
Treatment with narcotic pain medications(Anti-diarrheal agents such as loperamide and diphenoxylate are permitted).
History of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis).
History of abnormal liver function tests, including AST or ALT >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dL at screening (or within the previous 6 months, if known).
History of malignancy.
Women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.
Participation in other clinical trial within the past 3 months.